Genetic Analysis AS (FRA:8V8)

Market Cap	3.98M +28.5%
Revenue (ttm)	1.79M +2.4%
Net Income	-964.27K
EPS	-0.02
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	1,175
Open	0.0394
Previous Close	0.0396
Day's Range	0.0394 - 0.0394
52-Week Range	0.0350 - 0.1990
Beta	n/a
RSI	48.14
Earnings Date	May 29, 2026

About Genetic Analysis AS

Genetic Analysis AS, a science-based diagnostic company, develops diagnostic solutions for human microbiome market in the United States, Europe, and internationally. It offers GA-map, a platform for the analysis of the human gut microbiota; GA-map Dysbiosis Test that detects and characterizes dysbiosis; and GA-map Analyzer, a cloud-based software solution. The company also provides GA-map Discovery, a tool to search biomarkers and validate research findings or transfer the findings to a ready-to-use routine testing platform; GA-map Sample Colle...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2008
• Employees: 16
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 8V8

Financial Performance

In 2025, Genetic Analysis AS's revenue was 21.17 million, an increase of 2.36% compared to the previous year's 20.68 million. Losses were -11.41 million, -22.72% less than in 2024.

Financial numbers in NOK